BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-nhsa-2026-nrdl-commercial-innovative-drug-final-form-review-window@catalyst-calendar.local
DTSTAMP:20260720T200647Z
DTSTART:20260706T010000Z
DTEND:20260706T013000Z
SUMMARY:2026年医保目录及商保创新药目录形式审查复核结果窗口
DESCRIPTION:国家医保局已公示2026年医保目录和商保创新药目录初步形式审查结果，并说明公示后将复核并公布最终通过形式审查名单；该窗口影响创新药后续专家评审、谈判竞价和商业保险目录预期。\\nImpact score: 78\\nExpected: 最终形式审查名单将决定药品是否进入后续评审、测算、谈判竞价或价格协商流程，影响创新药收入峰值和支付端预期。\\nAffected: 512170.SH(etf\, mixed\, score 72)\; 600276.SH(subject\, mixed\, score 74)\; 09926.HK(subject\, mixed\, score 76)\; 01801.HK(subject\, mixed\, score 72)\; 688506.SH(subject\, mixed\, score 70)\\nSources: 国家医保局政策解读: https://www.nhsa.gov.cn/art/2026/6/29/art_105_21130.html\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-nhsa-2026-nrdl-commercial-innovative-drug-final-form-review-window
CATEGORIES:policy\,CN\,医保目录\,商保创新药\,创新药
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: 2026年医保目录及商保创新药目录形式审查复核结果窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: 2026年医保目录及商保创新药目录形式审查复核结果窗口
END:VALARM
END:VEVENT
END:VCALENDAR